CSL Behring commits on World Haemophilia Day

Latest News

CSL Behring has marked World Haemophilia Day by shipping more than 10 million units of its medicines to treat Haemophilia A to the World Federation for Haemophilia (WFH) Global Alliance for Progress (GAP) Program.

The GAP Program is designed to improve the diagnosis and treatment of bleeding disorders in developing countries, like Vietnam and Cameroon.

CSL said it was the first biotechnology leader to provide coagulation factor donations and financial support for the WFH Humanitarian GAP Program in a multi-year agreement in 2009. 

“This year’s theme for World Haemophilia Day is ‘Sharing Knowledge Makes Us Stronger,’” said CEO of the World Federation of Haemophilia, Alain Baumann. "There are millions of people around the world living with a bleeding disorder and using information and resources to improve diagnosis and access to care is one of our missions. A mission CSL Behring shares.” 

“Understanding patient needs and advancing their access to care is a part of CSL Behring’s promise to the global bleeding disorders community,” said Jens Oltrogge, the head of Global Commercial Development Hematology at CSL Behring. “WFH continues to improve patient lives through its humanitarian aid programs and this World Haemophilia Day we are proud to continue to support the organisation’s mission to ensure patients have access to the medicines they need.”

The company said the donation of coagulation factor concentrates is part of its ongoing promise to provide one or more of its medicines for bleeding disorders to the WFH over three years (2016 through 2018).